Ranbaxy Acquires Belgian Generics Company
Posted on: Friday, 31 March 2006, 12:00 CST
As part of its strategic drive to increase its presence in the European market, Ranbaxy Laboratories, India's largest pharmaceutical company, has acquired Ethimed NV, a Belgian generic pharmaceutical distributor.
The acquisition follows similar, recent strategic moves by Ranbaxy in Romania and Italy, and will allow Ranbaxy to anticipate local market dynamics and capitalize on the changing business landscape in Europe. It is the intention of Ranbaxy to manage operations throughout the Benelux countries from Ethimed in Belgium.
"Ethimed offers Ranbaxy a ready and robust distribution network to exploit new product opportunities in the future. It also provides the company, a strong base from where we can manage and expand our operations in the Benelux countries. We see this acquisition as strategic to our business in Europe," said Peter Burema, president of Ranbaxy's operations in Europe, CIS, Africa and Latin America.
The Belgium market is largely a branded, high priced market with increasing generic penetration. The acquisition positions Ranbaxy favorably to capture a significant portion of this expanding market.
Ethimed is an established generics company in Belgium with a significant customer network, especially among pharmacies. It has over 20 product registrations and is ranked number 10 among generic companies in Belgium.
Source: Datamonitor
Related Articles
- SIRO Group Appoints Scott L. Spector as President, Strategic Operations, for its European Business
- Informed Medical Communications Appoints New Senior Manager, Strategic Operations
- WABCO Reports Q4 and Full Year 2008 Results, Record Full Year 2008 EPS; Realigns Company to New Market Conditions; Provides 2009 Operating Framework
- Dr. Randhir Thakur Joining Applied Materials As General Manager of Strategic Operations
- New Market Report Covers Developments in Europe's Burgeoning Convergence Market
- Consumer Healthcare 2008 is Perfect for Hospital Marketing Executives and Strategic Planners
- Which Agents Are Driving the Growth of the Anemia Market in the United States, Europe, and Japan
- Holocom Networks Names Paul D. DeRosa Head of Marketing and Sales for Eastern U.S., Europe, Middle East and Africa
- Brandimensions Takes Online Market Intelligence to New Level With Acquisition of SEVENtwentyfour Inc.
- Neuropathic Pain Market to Reach $3.5 Billion By 2014, Despite Generic Neurontin Launch
 |
 |
User Comments (0)
RSS Feeds